title: Glucose challenge test (50-g GCT) in detection of glucose metabolism disorders in peritoneal dialysis patients: preliminary study.
abstract: BACKGROUND
  The aim was to evaluate the clinical utility of the oral glucose tolerance screening test (50-g GCT--glucose challenge test) for the detection of glucose metabolism disorders (GMD) in peritoneal dialysis (PD) patients with normal fasting glucose levels.
  
  
  METHODS
  The 50-g GCT was performed in 20 prevalent patients without history of diabetes before PD treatment onset, who had been on dialysis for a median time of 15.34 months. In addition, other indicators of glucose metabolism were measured: C-peptide, fasting insulin serum concentration, and the glycated hemoglobin level (HbA1c). The patients were prospectively followed for a median time of 25.8 months.
  
  
  RESULTS
  50-g GCT revealed GMD in 15 studied patients (75%)--impaired glucose tolerance in 11 patients (55%) and diabetes mellitus in four patients (20%). HbA1c and insulin resistance, estimated by homeostasis model assessment, were elevated in two (10%) and seven (35%) patients, respectively. In patients with GMD, dietetic and pharmacologic interventions were performed. When the 50-g GCT was repeated at the end of the observation period, 12 (60%) patients reported GMD, with no case of diabetes.
  
  
  CONCLUSIONS
  50-g GCT appears to be a simple and practical tool for the detection of GMD in PD patients with normal fasting glucose. Timely therapeutic intervention can effectively inhibit the progression of glucose intolerance during PD treatment.
authors.affiliation: Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, 213 Borowska St., 50-556, Wroclaw, Poland, kmadziarska@wp.pl.
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Madziarska
authors.forename: Slawomir
authors.initials: S
authors.lastname: Zmonarski
authors.forename: Jozef
authors.initials: J
authors.lastname: Penar
authors.forename: Magdalena
authors.initials: M
authors.lastname: Krajewska
authors.forename: Oktawia
authors.initials: O
authors.lastname: Mazanowska
authors.forename: Hanna
authors.initials: H
authors.lastname: Augustyniak-Bartosik
authors.forename: Tomasz
authors.initials: T
authors.lastname: Gołebiowski
authors.forename: Renata
authors.initials: R
authors.lastname: Klak
authors.forename: Waclaw
authors.initials: W
authors.lastname: Weyde
authors.forename: Marian
authors.initials: M
authors.lastname: Klinger
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D005215:Fasting / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D044882:Glucose Metabolism Disorders / Q000097:blood* / Q000453:epidemiology / Q000209:etiology; D005951:Glucose Tolerance Test; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D011044:Poland / Q000453:epidemiology; D015995:Prevalence; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D001786:Blood Glucose